Fast Five Quiz: Idiopathic Pulmonary Fibrosis Treatment

Guy W. Soo Hoo, MD, MPH; Zab Mosenifar, MD


December 13, 2022

Up to 80% of patients with IPF suffer from a chronic cough. In a study conducted by Birring and colleagues, it was suggested that the mechanism of cough in IPF might be disease specific. An inhaled cromolyn preparation was shown to reduce cough frequency by > 30% in patients with IPF, with relatively minor side effects.

Conventional antitussive therapy is typically not useful in the treatment of IPF.

The use of corticosteroids in IPF may increase mortality and should therefore be limited to patients who may be experiencing an exacerbation of IPF.

Thalidomide used for the treatment of cough in IPF has been shown to provide some improvement to quality of life, but related potential adverse effects can be severe.

Learn more about the management of cough in IPF.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.